Press releases

You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to therapy with the once-daily dual combination therapy, Relvar/Breo® (FF/VI), as a treatment for patients with asthma.

Read more - GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma Read more

ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Type II variation and extension applications to reduce the weight and age limit for the treatment of HIV in children and adolescents with Tivicay (dolutegravir) from at least 40kg to at least 15kg, in ages six to less than 12 years old, and to register new dose strengths of 10mg and 25mg oral tablets.

Read more - ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe Read more